Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 5/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.34 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.34 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18732391 | 0.84 | PDE3B (0.41) | BRD4PDE3BPDE3AP2RY12LTA4H | |
| SCHEMBL25748409 | 0.81 | BRD4 (0.41) | BRD4PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL29397620 | 0.81 | MAPT (0.43) | BRD4PDE3BPDE3AP2RY12L3MBTL1 | |
| SCHEMBL25748413 | 0.72 | BRD4 (0.37) | BRD4PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL4389091 | 0.70 | BRD4 (0.53) | BRD4PDE3BPDE3AP2RY12LTA4H | |
| SCHEMBL13490815 | 0.69 | BRD4 (0.47) | BRD4PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL29198000 | 0.68 | BRD4 (0.51) | BRD4PDE3BPDE3AP2RY12LTA4H | |
| SCHEMBL5842449 | 0.67 | KDM4E (0.55) | BRD4PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL18732228 | 0.67 | BRD4 (0.43) | BRD4PDE3BPDE3AP2RY12LTA4H | |
| SCHEMBL20521342 | 0.67 | MEN1 (0.39) | PDE3BPDE3AP2RY12L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| EP-3359544-B1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | Bayer Pharma AG (DE) | 2020-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | BRD4 1395/4885PDE3B 465/4885PDE3A 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.